GENEVA--(Marketwire - Jan 22, 2013) - Addex Therapeutics / Addex Announces Issuance of a Broad US Composition of Matter Patent for ADX71441 . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

ADX71441, a novel oral small molecule positive allosteric modulator of GABA-B receptor, on track for Phase 1 clinical testing in the first half of 2013

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that the United States Patent and Trademark Office granted Addex a composition of matter patent (US Patent 8,344,138) covering ADX71441 and other GABA-B receptor (GABA-BR) positive allosteric modulators (PAM). The claims of the issued patent also cover pharmaceutical composition and method of treatment using such GABA-BR PAMs. ADX71441 has been shown to be efficacious in a number of preclinical models, including in a validated model of Charcot-Marie-Tooth 1a (CMT1a), a rare hereditary motor and sensory demyelinating peripheral neuropathy.

"We are pleased that our efforts pioneering the field of allosteric modulation are being validated through the broad issuance of composition of matter and methods claims worldwide," said Bharatt Chowrira, CEO at Addex. "Our intellectual property estate continues to yield key patents protecting novel oral small molecules discovered utilizing our allosteric modulation technology platform. In particular, this new patent significantly enhances the value proposition for our ADX71441 program and we look forward to advancing ADX71441 into Phase 1 in the first half of 2013".

About ADX71441

ADX71441 is a potent, selective, orally available small molecule that is brain penetrant and shows good pharmacokinetic properties for once-daily dosing. Activation of gamma-aminobutyric acid subtype B (GABA-B) receptor, a Family C class of GPCR, is clinically & commercially validated. Generic GABA-B receptor agonist, baclofen, is marketed for spasticity and some spinal cord injuries, and used for overactive bladder (OAB), but is not commonly used due to severe side effects of the drug and rapid clearance. Orthosteric GABA-B receptor agonists have also shown clinical validation in gastroesophageal reflux disease (GERD). Addex' GABA-B receptor PAMs have shown efficacy in multiple preclinical models including: CMT1a, OAB, pain, osteoarthritis pain and anxiety.

About Addex Intellectual Property Portfolio

Addex Intellectual Property Portfolio includes 12 issued or granted patents and 43 pending patent applications in major pharmaceutical markets around the world. These patents describe and cover composition of matter, pharmaceutical compositions, method of use, formulations and method of manufacture of oral small molecules discovered and developed using Addex' pioneering oral small molecule allosteric modulation technology platform. In addition, these patents cover Addex' powerful biological assay systems important for identifying selective allosteric modulators with high fidelity and success rate.

Addex Therapeutics (www.addextherapeutics.com) discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGlu5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGlu2 positive allosteric modulator or PAM) is being developed in collaboration with Janssen Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in patients suffering from major depressive disorder. Addex also is advancing several preclinical programs including: GABA-BR PAM for CMT1a, spasticity in MS, pain, OAB and other disorders; mGlu4 PAM for MS, Parkinson's, anxiety and other diseases. In addition, Addex is applying its proprietary discovery platform to identify highly selective and potent allosteric modulators of a number of both GPCR and non-GPCR targets that are implicated in diseases of significant unmet medical need.

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGlu2, mGlu4, mGlu5, GABA-BR or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Addex Therapeutics via Thomson Reuters ONE

[HUG#1671908]